Chetan Vakkalagadda

Dr. Chetan Vakkalagadda

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CVChetan Vakkalagadda
Chetan Vakkalagadda
DDDanielle Dressler
Danielle Dressler
ZSZequn Sun
Zequn Sun
JFJoseph Fuchs
Joseph Fuchs
YLYingzhe Liu
Yingzhe Liu
NMNisha A. Mohindra
Nisha A. Mohindra
Purpose: Broad-based molecular testing with next-generation sequencing (NGS) is now the standard of care in advanced non-small cell lung cancer (NSCLC). Two approaches to molecular testing are (1) reflexive testing at pathologic NSCLC confirmation, often using an in-house molecular panel, and (2) send-out testing to private vendors, ordered by a clinician. This study explored the outcomes with reflex versus send-out testing. Methods: A retrospective chart review was conducted of patients diagnosed with de novo stage IV NSCLC in 2019 and 2020 at three hospitals in the same system, one academic hospital (Northwestern Memorial Hospital, or NMH) utilizing reflex, in-house NGS, and two community-based hospitals (Central DuPage Hospital, or CDH, and Delnor, or D) sending out tissue samples for testing. The outcomes assessed were the time from biopsy to results, biopsy to treatment, the incidence of first-line targetable mutations and the use of first-line targeted therapies, and overall survival. Results: In total, 191 patients met the inclusion criteria, 85 at NMH, 106 at CDH + D, and in total, 131 in 2019 and 60 in 2020. The time to results was significantly shorter with reflexive NGS when compared with send-out testing; the time to treatment was also shorter but not statistically significant. At CDH + D, the time to results was significantly shorter with a limited panel than with comprehensive testing, but the time to treatment was similar. NGS testing rates were 95% at NMH and 84.5% at CDH + D (p = 0.009), with 31.0% at NMH receiving 1L targeted therapies versus 20.8% at CDH + D (p = 0.08). In 2019, the median time from biopsy to treatment was 35 days at NMH and 38 days at CDH and Delnor; in 2020, time to treatment was 26 days and 37 days, respectively. Overall survival trended longer in 2020 relative to 2019 independent of site. Conclusion: Reflexive NGS testing is associated with a shorter time to actionable results and higher rates of first-line targetable mutations than send-out testing. In practices with send-out testing, limited panels had slightly faster turnaround times but no difference in time to treatment. If resources allow, reflexive NGS should be considered in healthcare systems for patients with NSCLC.

15 November 2023 in JTO Clinical and Research Reports
Verified
Journal Article
Open access
CVChetan Vakkalagadda
Chetan Vakkalagadda
JPJyoti D. Patel
Jyoti D. Patel
Despite the high activity of selective RET inhibitors in RET-driven NSCLC, resistance eventually develops and there is unmet need to better define therapeutic options for patients. This is a case of a patient initially thought to have no targetable alterations, then found to have a RET fusion, and subsequently HER2 amplification on three distinct biopsies. She was treated initially with chemotherapy and immune therapy, then switched to selpercatinib, and eventually had fam-trastuzumab deruxtecan added to selpercatinib. She also developed neuroendocrine differentiation at time of progression in the context of a p53 mutation, which is a known factor that can lead to small cell transformation. This patient’s case highlights the need for comprehensive molecular testing at both diagnosis and progression, as unexpected resistance mechanisms may be identified particularly for patients with uncommon driver mutations.

5 August 2025 in Clinical Lung Cancer
Verified
Journal Article
Closed access
CVChetan Vakkalagadda
Chetan Vakkalagadda
LBLeslie Bucheit
Leslie Bucheit
KCKeelia Clemens
Keelia Clemens
JSJayati Saha
Jayati Saha
NZNicole Zhang
Nicole Zhang
JPJyoti D Patel
Jyoti D Patel

23 October 2026 in Head & Neck
Verified
Journal Article
Closed access
CCCameron Chalker
Cameron Chalker
JBJason C. Burton
Jason C. Burton
AKAndy Kaempf
Andy Kaempf
JLJeong Youn Lim
Jeong Youn Lim
SLSarah Lowry
Sarah Lowry
EREric J. Roeland
Eric J. Roeland